Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q4 2020 · 10-K
Revenue$583.00M$583.00M+61.8% vs Q4 2019 Net Income$185.40M$185.40M+295.3% vs Q4 2019 EPS Diluted$3.44$3.44+282.2% vs Q4 2019 Operating Income$258,100,000+231.7% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$209,100,000+143.1% Margins · derivedOperating margin44.3%+22.7 pt vs Q4 2019
Net margin31.8%+18.8 pt vs Q4 2019
ended Dec 31, 2020 · filed Feb 19, 2021 · 50 d after period end